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NEUROFIBROMATOSIS TYPE 1: NATURAL HISTORY AND IMPACT ON 
QUALITY OF LIFE 
ZAIDAL ASEEL OBAGI 
ABSTRACT 
Neurofibromatosis Type 1 (NF1, von Recklinghausen’s disease) is among the 
more common autosomal dominant genetic disorders, with a worldwide incidence of 
approximately 1 in 3000 live births. NF1 can occur as either an inherited defect or as a 
spontaneous “de novo” mutation. NFI is caused by mutation of the neurofibromin gene 
that leads to a lack of neurofibromin in the cytoplasm of the cell. Neurofibromin, among 
other cytoplasmic roles, is a key regulator of certain cellular growth pathways. There is 
currently no cure for NF1. The disorder has an almost 100% penetrance, but is widely 
variable in its manifestation. NF1 is a progressive multisystem disorder, and the clinical 
manifestations tend to worsen with advancing age. NF1 typically manifests as multiple 
benign skin tumors (neurofibromas), café-au-lait spots, axillary freckles, optical nerve 
gliomas, iris hamartomas (Lisch nodules), learning disabilities, speech impairment, and 
orthopedic and cardiovascular problems.  More severe manifestations can cause vision 
loss, headaches, seizures, chronic pain, and orthopedic problems limiting physical 
activity. Patients with NF1 are four times more likely to develop malignancies than the 
general population.  
Several studies have shown that NF1 impairs the patient’s quality of life through 
association with more severe complications, impacts on the patient’s appearance, and 
through learning disabilities and depression. In both mild and severe cases, there seemed 
  vi 
to be an equal emotional impact on the patient. The psychosocial impact manifests in 
various ways, including loss of confidence and self-esteem. This can stem from insecurity 
due to an underlying learning disability or insecurity due to NF1-related cosmetic 
damage. The academic and emotional damage that follow the learning disability or the 
lack of confidence, if not treated with appropriate therapy, can go on to impact the 
patient’s relationships and career.  The patient may suffer from social exclusion, financial 
hardship and inability to obtain health insurance.  Patients may be unwilling to have 
children out of fear of passing on the mutation.  
This thesis seeks to present in detail the impacts on quality of life that 
neurofibromatosis causes, and discuss current management and treatment strategies that 
exist and what can be done further to improve these people’s lives.  Early individualized 
treatment is necessary to achieve better outcomes.  Support groups can help educate NF1 
patients and their family members and may help alleviate stress. Widespread public 
education about the condition would help remove the public stigma of Nf1, and allow for 
patients to feel normal and valued in society.  Early individualized treatment is necessary 
to achieve better outcomes.     
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INTRODUCTION AND HISTORY 
Neurofibromatosis historically was a general term used to describe the combined 
symptomatic manifestations of certain skin and bone pathologies, including benign 
tumors of nervous tissue origin termed neurofibromas.1,2 Certain cases of 
neurofibromatosis confused physicians and researchers alike, who noticed that the tumors 
manifested either mostly peripherally, or mostly within the vestibule of the ear and within 
the CNS.1  In 1987, the disease was split definitively by the National Institute of Health 
into Neurofibromatosis type 1 (NF1) and Neurofibromatosis type 2 (NF2), recognizing 
NF1 as the classic, peripherally-expressed disorder, and NF2 as the intracranial and CNS-
affecting disorder.1  Although NF1 is often described as a rare disease, its rate of 1 in 
3,000 births makes it more common than many other well-known genetic mutations 
including Cystic Fibrosis, Tay-Sachs and Huntington’s Disease (Table 1). 
Table 1. Prevalence of neurofibromatoses vs. other genetic mutations. 
Genetic Disorder Estimated Occurrence 
Neurofibromatosis Type 1 1 in 3,000 
Neurofibromatosis Type II 1 in 40,000 
Schwannomatosis 1 in 40,000 
Cystic Fibrosis 1 in 2,000 (white ethnicity) 
1 in 90,000 (other ethnicity) 
Tay-Sachs disease 1 in 2,500 (Ashkenazi Jewish ethnicity) 
1 in 250,000 (other ethnicity) 
Huntington’s disease 1 in 20,000 
Adapted from: Korf BR, Rubenstein AE. Neurofibromatosis: a Handbook for Patients, Families, 
and Health Care Professionals. New York: Thieme Medical Publishers; 2005. 
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 Neurofibromatosis type 1 (NF1) is caused by a genetic mutation in the Nf1 gene 
which encodes neurofibromin, a protein that is essential in regulating the growth 
pathways of various cells.2 Mutations in this gene are found in populations all over the 
world, regardless of ethnicity or gender, and is passed down in an autosomal dominant 
fashion.2 Although many cases are of hereditary origin, about half of the reported cases 
are from spontaneous mutations in individuals with no familial history of NF1.3 It was 
first officially recognized and described in medical literature by von Recklinghausen in 
1882, and for that reason is sometimes called von Recklinghausen syndrome.3 However, 
case reports for patients with neurofibromatosis type 1 date as far back as 1785, when a 
physician reported about a “wart man”, with symptoms aligning with a severe case of 
NF1.4 
Neurofibromatosis has since popped up in literature with varying medical impact. 
Perhaps the most historic (and misrepresentative) case of NF1 is the story of Joseph 
Merrick in London in 1844 who resembled having, and was misdiagnosed with, an 
extreme form of NF1 (Figure 1).5 He was then paraded around Europe in circuses as “The 
Elephant Man.”5 Merrick had many severe deformities, including an enlarged skull, 
enlarged limbs, and many tumorous protrusions from the skin.5 Merrick was 
posthumously rediagnosed with Proteus syndrome, a rare genetic mutation that may 
phenotypically resemble NF1 but has a different etiology.5a This famous case contributed 
greatly to the social stigma around NF1, and the disease colloquially being termed “the 
elephant man’s” disease.6 The stigma still persists today, in part due to a Hollywood box 
office hit under the same name.6 The fact that Merrick did not have NF1 has done little to 
 3 
abate the social stigma of patients with NF1 by people who describe them as having “the 
elephant man’s disease” but are unaware of its offensive history.6 
 On the one extreme on the spectrum of manifestation, it is possible for people 
with neurofibromatosis type 1 to live healthy, complication-free lives. In fact, despite 
having a near 100% penetrance, the level of symptoms of NF1 in individual patients is 
highly variable.3,7 It is stressed in the literature that neurofibromatosis is at first a disorder 
and not a disease.7 The difference between the two is that having a disorder does not 
necessarily lead to the development of medical problems; NF1 may even go undiagnosed 
by an unassuming physician.7  
Neurofibromatosis type 2, like type 1, is also an autosomal dominant genetic 
disorder; however, the mutation occurs on a different chromosome and occurs much less 
frequently than NF1 (Table 1).1 NF2 stems from a mutation on chromosome 22, whereas 
NF1 stems from a mutation on chromosome 17.7 Typically, NF2 manifests intracranially 
within the ear canal, or in the meninges, and demonstrates different diagnostic symptoms 
than that of NF1.1 
A third type of neurofibromatosis has recently been described in the literature, 
termed Schwannomatosis.7  It is believed to occur at the same rate and stem from the 
same chromosome as NF2; however, it manifests itself differently than either NF1 or 
NF2. These manifestations often include pain (not usual in NF1 and NF2) and 
schwannomas, tumors of specifically Schwann cell origin (also seen in NF2) instead of 
neurofibromas, tumors of both Schwann cell and other nerve-associated cells’ origin.7 
NF2 and Schwannomatosis often have a delayed onset of symptomatic expression 
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(usually not appearing until adulthood), whereas a diagnosis of NF1 can be made on an 
infant, based on characteristic symptomatic manifestations that are discussed later.7  
This thesis seeks to present in detail the impacts on quality of life that 
neurofibromatosis causes, and discuss current management and treatment strategies that 
exist and what can be done further to improve these people’s lives. Indeed, the quality of 
life for people with neurofibromatosis type 1 can be quite poor. There is yet no gene 
therapy that exists to repair the mutation. Instead, clinicians mainly focus on treating each 
symptomatic manifestation separately.7 The disorder, once it becomes a disease, 
manifests itself clinically in many ways including: neurofibromas (on the skin and within 
the body), cardiovascular problems such as hypertension, vessel obstruction or 
hemorrhage, Lisch nodules in the eyes, hyperpigmented macules on the skin termed café-
au-lait spots, learning disabilities such as a reduced IQ or mental capacity for certain 
types of cognitive function, and more.2,7,13 In addition, there is a large psychosocial 
impact on patients who fear how their disabilities may impact their status in the minds of 
others.7 There is also a constant fear that their condition can become malignant and 
progress into one or more forms of cancer (which occurs in NF1 patients at around a 
frequency of 5%).8  
Based on the prevalence of each type of neurofibromatosis, this thesis focuses 
primarily on the impact on quality of life for patients affected with NF1. However, many 
of these symptoms also affect patients with the other types of neurofibromatosis. Thus in 
focusing on the following cases, this thesis will emphasize the need to increase the 
quality of life for patients suffering from all types of neurofibromatosis.  
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Figure 1. The Elephant Man and severe neurofibromatosis type 1. (a) Joseph Merrick, 
exhibited as The Elephant Man, was misdiagnosed with an extreme case of NF1, and only 
recently rediagnosed with Proteus syndrome (British Medical Journal, 1890; Tibbles and Cohen, 
1986). (b) A patient with an extreme case of NF1, with many cutaneous neurofibromas and one 
large sacral plexiform neurofibroma (Antônio et al., 2013).  
A B 
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MANIFESTATION AND PROGRESSION 
Neurofibromatosis type 1 has a nearly 100% genetic penetrance, but is also highly 
variable in respect to its manifestation, with a spectrum of extremely mild to extremely 
severe cases.9 The complications arise due to a lack of expression of the protein 
neurofibromin. Neurofibromin is mostly expressed in neurons and cells that support them 
such as Schwann cells, oligodendrocytes and astrocytes, but is also expressed in 
leukocytes, the adrenal medulla, and smooth muscle in the vasculature.10,11 NF1 is a 
progressive disease, and symptoms tend to manifest or worsen as the patient ages (Table 
2). There is no known treatment for neurofibromatosis type 1.2 
Table 2. Progression pattern of neurofibromatosis type 1. 
Age of Patient Complications 
Birth Café-au-lait spots, Pseudoarthosis, 
External, Cognitive disabilities, Visible 
plexiform neurofibroma 
Childhood Freckling, Optic glioma, Severe scoliosis 
Teenage/Young adult Cutaneous neurofibroma, Lisch nodules, 
Short stature, Precocious puberty 
Adult Malignancy, Pheochromocytoma, 
Paraspinal plexiform neurofibroma 
Adapted from: Tonsgard JH. Clinical Manifestations and Management of Neurofibromatosis 
Type 1. Seminars in Pediatric Neurology. 2006;13(1):2. 
  
Because of the many types of mutations that can occur in patients with NF1, most 
clinicians today forego genetic testing in favor of a clinical diagnostic criteria that 
requires examining the whole body and the patient presenting with at least two symptoms 
to make a positive NF1 diagnosis (Table 3).2 Not every known manifestation of NF1 
happens to every patient. Some manifestations, such as the neurofibromas and café-au-
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lait spots, are highly common among all NF1 patients and occur in over 95% of cases 
(Figure 2).12 Certain manifestations, such as scoliosis and malignancy, are much rarer and 
occur in 10% or less of total cases.12  
Table 3. Clinical diagnostic criteria for NF1 
 
6 or more café-au-lait spots, >5 mm before puberty, > 15 mm after puberty 
Axillary, groin or neck freckling (non-sun exposed freckling) 
2 or more cutaneous neurofibromas 
1 plexiform neurofibroma 
2 or more iris Lisch nodules 
Optic glioma 
NF1 characteristic bony lesion (pseudarthrosis, scoliosis, etc…) 
First degree relative with NF1 
►2 or more of the above are required for a diagnosis of NF1. 
 
Adapted from: Tonsgard JH. Clinical Manifestations and Management of Neurofibromatosis 
Type 1. Seminars in Pediatric Neurology. 2006;13(1):3 
 
 
Figure 2. Mild manifestations of neurofibromatosis type 1. Mild manifestations of NF1 
include spots of discoloration termed café-au-lait spots, and benign tumors termed neurofibromas, 
both of which are depicted above. The neurofibromas are tumors caused by nerve and nerve-
associated cells. (Accrochoc, 2000)
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Neurofibroma 
One of the hallmark manifestations of NF1, a neurofibroma is a dysplastic 
growth of peripheral nerve and nerve-associated cells, including Schwann cells, 
fibroblasts, perineural cells, mast cells, axons, and blood vessels.13 A neurofibroma can 
present itself in four different ways. 1) Superficial cutaneous neurofibromas present as 
circular, buttonous outgrowths on the skin, originating from superficial nerves (Figure 
3). 2) Subcutaneous or dermal neurofibromas are localized nerve tumors that begin in 
the dermis, deeper than the superficial counterpart, and closer to pain receptors; 
therefore they sometimes induce localized pain.14 3) Nodular plexiform neurofibromas 
and 4) diffuse plexiform neurofibromas are less localized, and more sheet-like forms of 
outgrowth, derived from the uncontrolled growth along the nerve or from multiple nerve 
fascicles instead of just on one part of the nerve (Figure 3).14 Nodular plexiform 
neurofibromas present subcutaneously or on the skin, whereas diffuse plexiform 
neurofibromas affect all layers of the skin, can be entirely internal, and can even affect 
the dorsal spinal roots, the sympathetic network of nerves, and nerves in muscle, bone 
and the viscera.14 
 Neurofibromas usually start at puberty and increase in number with age, ensuring 
that almost all adults with NF1 have at least one.15 Over 95% of NF1 patients have 
neurofibromas.12  The cutaneous, buttonous form is the most common form; fortunately 
this form is usually benign and can be removed surgically. The cutaneous neurofibromas’ 
impact on the patient is mostly psychological and cosmetic. One-third of NF1 patients 
develop the plexiform variant of neurofibroma.16 The diffuse subtype of plexiform 
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neurofibroma is usually congenital, but can be difficult to detect in infants due to its deep 
and often asymptomatic manifestation.16 This variant can be more damaging to the 
patient, with its greater difficulty to be surgically removed due to its depth within the skin 
or healthy tissue, its ability to influence underlying bone growth leading to limb 
asymmetry, and its greater chance at becoming malignant.15,17,18   
 The danger of malignancy is much higher in patients with the plexiform 
neurofibromas. Around 10% of plexiform neurofibroma, or 3% of total NF1 patients, 
patients develop a specific type of malignancy termed a malignant peripheral nerve 
sheathe tumor (MPNST).12,19 The greatest risk of developing this type of malignancy is in 
patients between the age 15-40 years old.12 This tumor is highly malignant, associated 
with a lot of pain, and metastasizes quickly to other tissues, particularly the lungs.20 
Chemotherapy and radiation therapy do not work very effectively against MPNST and 
survival rates are estimated to be less than a year for patients with MPNST.20  
a)              b)      
Figure 3. Plexiform vs. cutaneous neurofibromas. (a) A plexiform neurofibroma 
demonstrating the sheet-like outgrowth along the length of the nerve or neural network (Antônio 
et al., 2013). (b) A cutaneous neurofibroma demonstrating its localized, buttonous appearance 
(Al Bisher et al., 2011). 
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Café-au-lait spots and freckling 
 Café-au-lait spots, like neurofibromas, are a hallmark manifestation of NF1 and 
also occur in over 95% of patients.12 They are usually present at birth and are often the 
first diagnostic measure that a clinician uses to diagnose NF1. Some healthy patients may 
develop café-au-lait spots and not have neurofibromatosis type 1, but the presence of 6 or 
more spots is suggestive of NF1. Patients with NF2 can present also with café-au-lait 
spots, but never more than 6, which is one characteristic for a clinician to use to be sure 
he is dealing with NF1.7 Café-au-lait spots present as hyperpigmented round or oval-
shaped spots and must be at least 0.5 cm in diameter in children or greater than 1.5 cm in 
adults to be considered a café-au-lait spot (Figure 2).12 These spots do not become 
neurofibromas. Similar to neurofibromas, the number (and size) of spots increase with 
age.12 They are not necessarily caused by an increase in melanocytes within the spot; 
instead some studies suggest the melanocytes within the spot are producing giant pigment 
granules.21 One knockout gene study explores the development process of melanocytes, 
since both Schwann cells and melanocytes share a precursor cell of neural crest origin, 
and are both impacted in neurofibromatosis.22 They discovered a certain developmental 
window for precursor cells fated to become melanocytes, wherein insufficient 
neurofibromin protein from the mutated Nf1 gene causes a change in melanocyte 
colonization within the dermis and epidermis.22 
 Similar to café-au-lait spots, diffuse freckling of the skin, and freckling of the 
axilla and groin region, is common in NF1 and presents as many small, hyperpigmented 
spots on the skin.12 Freckling usually begins in childhood, around the age 5-7.12 
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Optical complications 
The development of Lisch nodules within the iris is a manifestation unique to 
neurofibromatosis type 1 and is therefore a useful diagnostic measurement for clinicians.7 
Very rarely do Lisch nodules present unaccompanied by NF1, although it is possible.22 
Lisch nodules are present in 90 to 100% of patients with neurofibromatosis.23 They begin 
to form during the teenage years, and are non-vision impairing.12 They are benign tumors, 
specifically melanocytic hamartomas, and their origin can be traced to the same precursor 
cells impacted by the lack of neurofibromin that also generate the melanocytes involved 
in café-au-lait spots.23 They present as reddish-brown spots, usually in the bottom half of 
the iris (Figure 4).12 There is a correlation between age and the number of Lisch nodules 
present, suggesting that more nodules develop with age.23 Although the largest Lisch 
nodules can be perceived with the naked eye, often a slit lamp exam is needed to detect 
the earliest cases of Lisch nodules.23 
 
Figure 4. Lisch nodules of the iris. Visible in the iris of this patient are the Lisch nodules: 
reddish-brown spots aggregated mostly in the bottom half of the iris. More nodules appear with 
age, and are benign and asymptomatic. (Adams et al., 2011) 
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 Other common optical complications beyond Lisch nodules include optical 
gliomas, which occur in 15 to 20% of NF1 patients.24 These gliomas are of astrocytic 
origin, due to unregulated astrocytic growth, again stemming from the lack of the protein 
neurofibromin in cellular growth regulation.24 The mean onset-age of these tumors is 
quite young, occurring on average in children 4.2 years old.25 Although neurofibromin 
regulates cellular growth in astrocytes through a different pathway than in other tumorous 
cell types involved in neurofibromatosis, the result is the same: a benign tumor that 
increases in size with age.25,26 Although the optical glioma can occur along any part of 
the optic nerve, and most tumors are asymptomatic. The most problematic places that 
optical gliomas can occur are close to the eyes, causing proptosis, or close to the 
hypothalamus where it can influence hypothalamic function and cause precocious 
puberty and short stature.24,25 Optical gliomas can also lead to visual loss, with the 
greatest risk being between 15 months and 7 years old; children between these ages with 
NF1 should be checked regularly by an opthomologist.25 Plexiform neurofibromas in the 
orbit is associated with optical gliomas.12  
 
Learning disabilities 
 It was once feared by parents that children with NF1 have a much greater chance 
to develop mental retardation, due primarily to sample bias by older studies on 
institutionalized patients with NF1.7,27 It is now known that people with NF1 do on 
average have lower IQs than the normal mean (one IQ study found an average of 88.6 
SD±14.6 in people with NF1 vs 101.6 SD±14.2 in the control group) but the average IQ 
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of patients with NF1 is still much greater than what is considered intellectual impairment 
(IQ < 70).28 Furthermore studies show that there are children with NF1 who possess 
average or above-average IQ, and that the IQ distribution is bimodal, with a peak in the 
normal range and a peak in impairment range.12,27 There is a slightly higher incidence of 
mental retardation in patients with NF1, but the incidence of mental retardation in 
patients ranges in various studies from the normal 3% found in the general population to 
8% at the greatest.27,28  
 Besides a slightly lower average IQ, other types of cognitive impairments do 
often manifest themselves in patients with NF1, presenting in up to 65% of patients with 
NF1.29 These impairments can alter the ability to think and learn properly, due to the lack 
of a key brain function. There is no specific learning disability that manifests in patients 
with NF1, but various learning disabilities can present in patients.29 For instance, lacking 
the ability to process written or spoken language can lead to speech or educational 
deficiencies; lacking the ability to integrate visual signals into motor movements can lead 
to poor coordination and clumsiness.7 Some rat model studies support the hypothesis that 
NF1 impairs spatial learning, leading to a decreased ability for the patient to navigate and 
orient his or herself with the surroundings, or perform tasks that involve substantial hand-
eye coordination.30 Attention deficit disorder is another common manifestation in patients 
with NF1.7 These disabilities are often found more in males than females and often 
persist into, or manifest in, adulthood.7 It should be reemphasized that these impairments 
are usually specific to certain brain functions and do not impair a patient’s innate 
intelligence.7,27 However, should impacted patients not undergo proper management and 
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therapy for the presenting learning disability, the impairments may impact patients’ 
educational and professional career as well as self-esteem and happiness. 
 
Orthopedic manifestations 
 Deep diffuse plexiform neurofibromas’ that grow in limbs, and their effects on 
underlying bone growth, can be the cause of many of the orthopedic problems seen in 
patients with NF1. Diffuse plexiform neurofibromas are often congenital, and can grow 
rapidly during adolescence and infancy; they may displace, erode or demineralize the 
adjacent bone by increasing pressure or increasing the surrounding vasculature.7 The 
most common orthopedic problems include scoliosis, congenital pseudarthrosis of an 
extremity, asymmetric overgrowth of an extremity, or short stature.31,32  
Scoliosis is seen in about 10% of NF1 patients, and can range from mild to severe 
curvatures of the spine.31,32 It is believed that scoliosis is secondary to an adjacent spinal 
diffuse plexiform neurofibroma inducing vertebral dysplasia or erosion.12 Mild scoliosis 
can be treated with a brace that is worn underneath clothing.7 A small subset of patients 
with scoliosis can develop a severe form termed dystrophic scoliosis, manifesting in 
childhood, forming a sharp angle of the spine and untreatable with a normal brace; 
surgery is the preferred treatment method for dystrophic scoliosis.7,32  
Pseudarthrosis occurs in 3% of NF1 cases, often present at birth or shortly after, 
and mostly affects the tibia or forearm. Pseudarthrosis is a bone fracture that the body 
believes to be two independent bones and thus does not attempt to fuse the fracture, and 
abnormal bowing of the limb can occur (Figure 5). Pseudarthrosis is difficult to treat 
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surgically and prophylactic bracing is recommended; in the most severe cases where 
surgery does not help, limb amputation may improve the quality of life of the patient.7,12 
Bone overgrowth of one limb can also occur, possibly induced by an adjacent plexiform 
neurofibroma, and it most notably affects the legs.7 Asymmetry can be prevented if 
treated early enough with methods to destroy growth plates or delay the growth of the 
abnormal limb to allow the other limb to catch up in length.7  
An average shorter stature is common in patients with NF1, even when they 
present with normal growth hormone levels and without any hypothalamic-influencing 
optical gliomas; the etiology for this is yet unknown, but in some cases can be treated 
with growth hormone therapy.33 
 
Figure 5. Pseudarthrosis and bowing of the limb. Congenital pseudarthrosis can present itself 
in patients with NF1, often shortly after birth, and most often in the tibia. It is caused by a failure 
of regular bone formation or a fracture in the bone that the body does not act to fuse. Continued 
dysplastic bone growth or subsequent fractures can lead to the bowing of the limb as seen above. 
(Kalra and Agarwal, 2012) 
 16 
Vascular manifestations 
The lack of neurofibromin as a regulator for various cells’ growth affects many 
other places in the body besides the hallmark skin and brain manifestations discussed 
above. The body’s vasculature is surrounded by nerves and neurofibromatosis can affect 
these as well. Although vasculopathy overall is not very common, the most common 
manifestation of NF1 in the vasculature is hypertension, with renal artery stenosis or 
dysplasia being the primary cause.34,35 The frequency of renal artery dysplasia is 1% in 
NF1 patients.34 Blood vessels of any size can be susceptible to stenosis or occlusion due 
to NF1, and most patients with symptomatic conditions present with multiple affected 
vessels.11 Pregnancy can increase the risk of vasculopathy with NF1.11 
Cerebrovascular stenosis or occlusion is another possible vasculopathy caused by 
NF1, manifesting most commonly in the carotid arteries. It is less common than renal 
artery stenosis, but can ultimately lead to aneurysm formation, hemorrhage and early 
mortality in patients with NF1.36 Statins are useful in reducing vascular inflammation and 
treating early signs of aneurysm.36 
Congenital heart defects (CHD) have been found in 0.4-6.4% of patients with 
NF1, and may stem from developmental problems related to a lack of neurofibromin in 
key developmental cells of the endo and myocardium.11 These defects include pulmonary 
valve stenosis and tetralogy of Fallot, cardiovascular problems which can lead to 
cyanosis if left untreated. Tetralogy of Fallot refers to a combination of 4 anatomical 
malformations of the heart, including ventricular septal defect, biventricular connection 
of the aortic root, obstruction of the right ventricular outflow tract, and right ventricular 
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hypertrophy.11a  Complete heart repair surgery is usually performed on neonates with 
tetralogy of Fallot with an 85% long-term survival rate.11a  In general, CHDs are rarer 
NF1 manifestations, and are usually found in severe cases of the Nf1 gene mutation.11 
 
Malignancy 
 Malignancy is another fear of patients with neurofibromatosis type 1. Excluding 
neurofibromas and optical gliomas, which are relatively common in NF1 patients as 
discussed above, one study found the overall risk of a malignant neoplasm in patients to 
be 6.9%.37 The frequency of non-CNS tumor formation (4.9%) was slightly higher than 
the frequency of CNS tumors (2%), with the frequency of a neoplasm in general higher 
for patients with NF1 than in their relatives (3.2% for non-CNS and 1.2% for CNS 
tumors in relatives).37 Another study found the overall malignancy risk in NF1 patients 
slightly lower at 4.4%, with non-CNS tumors (2.9%) still more common than CNS 
tumors (1.5%), excluding neurofibromas and optic gliomas.38 
 The most common non-CNS tumor, besides neurofibromas, that appear in patients 
with NF1 are the malignant peripheral nerve sheathe tumors (MPNST) discussed earlier 
and which carry a high mortality risk. In addition, NF1 patients have higher frequencies 
of leukemia, including chronic myeloid leukemia, acute lymphoblastic leukemia, non-
Hodgkin’s lymphoma, and juvenile myelomonocytic leukemia (JMML).39 JMML is a 
rare form of leukemia affecting children.  In one study 14% of cases were children with 
NF1.40 Sarcomas, specifically rhabdomyosarcoma, also have increased frequencies in 
patients with NF1. Rhabdomyosarcomas are usually aggressive, developing from the 
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precursor cells to muscle, and mainly manifest in the head and neck, urinary and 
reproductive organs, or extremities.7,39 They can cause problems if they start to occlude 
the bladder or put pressure on the eye.7 Pheochromocytomas are also more common in 
patients with NF1; a pheochromocytoma can lead to an excess of circulating epinephrine, 
and causing excess sweating, high blood pressure and heart rate, and poor blood sugar 
management.7,39 
 CNS tumors in patients with NF1 include the relatively common optical gliomas 
discussed above caused by an overgrowth of astrocytes; these are referred to as Grade I 
astrocytomas and are usually benign and asymptomatic. They can cause vision or 
endocrine problems if the tumor grows near eyes or hypothalamus respectively. 12 Other 
astrocytomas, termed grade III and IV astrocytomas, can arise and grow in any part of the 
brain or spinal cord, but most commonly occur in the cerebellum, cerebrum or brain 
stem.12,39 These tumors can be aggressive and symptomatic, causing seizures, headaches, 
fainting, comas .7 Chemotherapy or invasive surgery may be required to treat the brain 
tumor if the patient’s health is compromised, but a positive outcome is not always 
guaranteed and the tumor can return.12 
 
Other manifestations 
 Macrocephaly is a common condition in patients with neurofibromatosis type 1, 
believing to affect between 30 to 40% of patients with NF1.7 The cause for macrocephaly 
is still unknown. Both the skull and the brain are usually enlarged, with no other 
correlating physical symptoms nor any correlation between the skull and brain size and 
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any learning disabilities.7 It is believed the enlargement could be due to a larger presence 
of white matter around the grey matter in the brains of NF1 patients.41 
Hydrocephalus affects about 1-2% of NF1 patients, causing an excess buildup of 
fluid in the ventricles of the brain.7,38 This can compress parts of the brain and lead to 
headaches, visual complications or seizures.7 A ventricle shunt inserted surgically is the 
common treatment.7 
 Headaches and seizures, independent of any underlying brain tumor, are also 
common in patients with NF1; they affect about 10 to 20% of patients, with headaches 
(including migraines) being more common than seizures.12,38 Medication used to treat 
headaches and seizures in the general population are also effective in patients with NF1.12 
 Table 4 provides a review of the major complications that may be found in the 
patient due to Nf1. 
Table 4. Major complications of NF1 by system. 
 
SYSTEM COMPLICATIONS 
SKIN Cosmetic (cutaneous neurofibroma) 
CNS Learning disability; Glioma; Seizures; 
Spinal cord compression by tumor 
PERIPHERAL NERVES Neurofibroma; Malignant peripheral 
nerve sheath tumor (MPNST) 
CARDIOVASCULAR Hypertension (renovascular), Vascular 
stenosis; Hemorrhage 
GASTROINTESTINAL Lumenal obstruction; Constipation 
ENDOCRINE Pheochromocytoma 
SKELETAL Skeletal dysplasia; Bone cysts; Scoliosis 
GROWTH Short stature; Macrocephaly 
HEMATOLOGICAL Nonlymphatic leukemia 
Adapted from: Korf BR. Malignancy in Neurofibromatosis Type 1. The Oncologist. 
2000;5(6):478.  
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PATHOGENESIS OF NF1 AND THE IMPORTANCE OF NEUROFIBROMIN 
Genetics introduction 
 
Most people have two functional copies of any gene, noted shorthand as +/+, and 
which typically ensures the proper amount of a protein is being expressed by the cells. 
When one copy of the gene is aberrantly expressed or not expressed at all, it is termed 
haploinsufficiency and written as +/-. In haploinsufficiency, depending on the type of 
mutation, either a mutated, nonfunctional form of the protein is produced alongside the 
normal version, or simply less of the normal protein is produced. If both functional copies 
of the gene are compromised, it is written as -/- and the gene is deemed homozygously 
inactivated. Various types of mutations exist which may or may not compromise a gene’s 
function (Table 5). These mutations happen at the level of nucleotides, which are the 
building blocks of the genome. Groups of 3 nucleotides, termed a codon, code for any 1 
of 20 amino acids, and different mutations to the codon can alter the desired amino acid, 
or even terminate protein synthesis early.  
In addition, there exists variability between cell types as to the level of expression 
for any given gene. This leads to predictable symptomatic manifestations for certain 
genetic disorders based on which cell types are most dependent on the mutated gene.7 At 
given time within a person’s lifetime, expression of a certain gene by the various cell 
types can increase or decrease; the signals for these changes in expression of a gene falls 
underneath the term “epigenetics”, and these signals can be transmitted by hormones or 
various other stimuli.7 
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Table 5. Various types of mutations. 
Type of Mutation Effect on Protein 
Silent mutation A substitution of one type of nucleotide 
for another in the gene, but which does 
not change the coded for amino acid. 
Leads to no change to the protein. 
Insertion mutation An insertion of new nucleotides into the 
genetic code. If the insertion was not in a 
multiple of 3 nucleotides, it could 
fundamentally shift the reading frame of 
the gene, vastly altering the protein. If 
insertion is 3n nucleotides, it will lead to a 
larger and possibly nonfunctional protein. 
Deletion mutation A deletion of a certain number of 
nucleotides in the gene, or possibly the 
entire gene itself. If the deletion is not in a 
multiple of 3 nucleotides, it could 
fundamentally shift the reading frame of 
the gene, vastly altering the protein. If 
deletion is 3n nucleotides, it will lead to a 
smaller and possibly nonfunctional 
protein. If the entire gene is deleted, none 
of the protein will be expressed. 
Missense mutation A substitution of one nucleotide for 
another which changes the coded for 
amino acid. This may or may not lead to a 
change in the folding structure of the 
protein, and may or may not alter the 
protein’s function. 
Nonsense mutation A substitution of one type of nucleotide 
for another, which changes the codon 
from coding for an amino acid to coding 
for a stop signal. This leads to a smaller 
and possibly nonfunctional protein. 
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Neurofibromin 
The gene for neurofibromin is found on chromosome 17. Specifically, it is located 
at 17q11.2. In this nomenclature, the “q” refers to the long arm of the 17th chromosome, 
and the “11.2” references how far away from the centromere the gene is.2,42 On the other 
hand, NF2 is caused by a mutation of a gene found on chromosome 22 for a protein 
dubbed “Merlin” or “Schwannomin”.7 Although found on separate chromosomes, both 
neurofibromin and merlin have a similar primary function which is cellular growth 
suppression; for this reason, both proteins are known as tumor suppressor proteins.7 In 
addition to regulating various cellular division pathways, additional functions for both of 
these proteins have recently been discovered: neurofibromin has been found to have other 
cytoplasmic roles such as stabilizing microtubules, and merlin has been found to be an 
important signaling protein in cell-to-cell and cell-to-ECM interaction.7,43 The many 
functions of these proteins are yet to be fully understood, and may explain why so many 
complications beyond tumor growth occur when a patient presents with NF1 or NF2. 
Neurofibromin’s primary function as a tumor suppressor protein is performed by 
its regulatory role in two pathways: the Ras-GAP pathway and the cAMP-PKA pathway.7 
Most of the research on neurofibromin’s role as a regulator involves its role in the Ras-
GAP pathway.7 The Ras-GAP pathway is an important pathway for cell proliferation, 
beginning when a receptor is triggered by certain growth factors.44 Ras has two main 
conformations: bound to GTP or to GDP. Ras is a GTPase, albeit a slow one on its own: 
it will hydrolyze a GTP molecule into GDP given enough time.44 NF1 is considered a 
GTPase Activating Protein (GAP), and will expedite the ability of Ras to hydrolyze GTP 
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to GDP. When Ras is in its GTP bound state, which it assumes after growth factor 
activation, it becomes the gas pedal to cell proliferation.44 Ras-GTP will lead to the 
activation of many downstream proteins that in turn lead to cell proliferation and cell 
survival (Figure 6).44 Neurofibromin acts as the brakes on cell proliferation, by inducing 
Ras to hydrolyze GTP to GDP, rendering it to its inactive state.44 Because Ras-induced 
cell proliferation is so prevalent among all cell types, it is easy to picture the dire 
consequences of unchecked, widespread cellular growth by the absence of neurofibromin, 
which is meant to keep growth in check.44 Neurofibromin’s importance as the key GAP, 
vs. other GAPs, for Ras regulation varies between certain cell types, leading to the 
manifestations of unregulated growth of specific cell types seen in NF1.45  
 
Figure 6. Neurofibromin’s role in regulatory pathways. Neurofibromin acts as a regulator on 
the Ras-GAP pathway and the cAMP-PKA pathway. Neurofibromin downregulates cell 
proliferation by inducing the Ras-GDP inactive state. Neurofibromin also upregulates adenylate 
cyclase, leading to higher intracellular cAMP levels, greater PKA activity, and ultimately less 
cellular growth. (Williams et al., 2009). 
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 The cAMP-PKA pathway is another important part of neurofibromin’s role in 
cellular cytoplasmic function and growth regulation. Neurofibromin acts as an 
upregulator to adenylate cyclase, a protein activated by extracellular signals binding to 
their respective receptors. Adenylate cyclase forms cAMP from ATP molecules, and 
cAMP goes on to activate PKA, an important cytoplasmic kinase with many functions, 
one of which is to regulate the growth of certain cell types.26 High cAMP also activates a 
protein named Rap1, which has anti-Ras activity.26 This cAMP-PKA growth regulation 
pathway with respect to neurofibromin is most studied in astrocyte growth and function, 
where a lack of neurofibromin can have consequences of unchecked astrocytic growth, 
glioma formation, and learning disabilities.26 However, other cell types are also known to 
rely on cAMP-PKA signaling for normal function and growth as well. For example, some 
studies show that neurofibromin’s absence in respect to cAMP-PKA signaling, in 
addition to any Ras-GAP abnormalities, plays a role in Schwann cell cytoplasmic 
dysfunction and abnormal growth seen in NF1 manifestations.26,45 
 
Pathogenesis 
 All individuals that have NF1 are born with one functional copy of the 
neurofibromin gene and one mutated or deleted copy of the gene.2 If in gestation there 
had been two nonfunctional copies, the embryo would have many developmental issues 
stemming from the lack of neurofibromin as a regulator for key developmental cells.46,47 
These developmental cells include the neural crest cells, which have shown particular 
sensitivity to neurofibromin levels, and which are known to orchestrate development of 
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key tissue such as bones, neurons, smooth muscle, endocrine, and adipose tissue among 
others.46,47 In mouse models, studies have demonstrated that embryos homozygously 
missing the gene for neurofibromin, termed “Nf1 knockout mice”, cannot complete the 
development of key parts of the heart which are neural crest cell induced, including the 
myocardial structure and the right ventricle cardiac outflow tract, and that the embryo 
terminates at day 14 of gestation.11 
 The gene sequence for neurofibromin is 335,000 base pairs long with 59 exons: 3 
of which are alternatively spliced to create related but also distinct forms of 
neurofibromin.48 These variant forms of neurofibromin add complexity to the 
understanding of the Nf1 gene mutations, with the possibility of a mutation affecting only 
one spliced form of neurofibromin over another.7 This variability would explain some of 
the differences in form and degree of manifestation seen among patients with NF1 but 
with different forms of mutation. Indeed, over 500 different mutations have been noted in 
subjects with NF1, ranging over all the types explained in Table 5; however, the most 
common mutations result in a shorter, nonfunctional form of neurofibromin.7 
 The many forms of mild to severe types of mutations found in the genome of 
people with NF1 can play a large role into the wide range of manifestations seen among 
patient populations with NF1.7,49 Indeed, some researchers have found that in the most 
severe manifestations of NF1, the entire Nf1 gene and even some adjacent genes have 
been deleted.49 Between 5-20% of subjects present with this full gene deletion, and have 
more severe manifestations such as dysmorphisms, cardiac abnormalities, mental 
retardation, developmental delays, early on-set neurofibromas, and increased risk of 
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MPNST formation, 49,50 In addition, epigenetic factors may also contribute to the 
variability of manifestations seen in patients.42 Epigenetic factors are factors separate 
from any changes to the actual neurofibromin genetic code, but which can influence the 
expression of the gene. These include, but are not limited to: cellular responses to various 
hormones, epistasis with other genes, gene methylation, and exposure to environmental 
or infectious agents.42 The relative uncontrollability of these epigenetic factors plays a 
role in the diverseness and age-relatedness of manifestations. It may also explain why 
identical siblings with NF1 can present with different manifestations.7,42 
  
Haploinsuffiency  
As noted earlier, patients with NF1 are almost all born with cells heterozygous for 
one normal gene and one mutated or deleted gene. Haploinsufficiency causes lower 
levels of functional cytoplasmic neurofibromin.44 This in turn leads to less regulation of 
the Ras-GAP and cAMP-PKA pathways, and higher sensitivity by cells to external 
stimuli that activate these pathways, such as growth factors.44 Haploinsufficiency is 
enough to cause cytoplasmic abnormalities, loss of proper cellular function, and lead to 
many characteristic manifestations in NF1. Some cell types are more sensitive to 
neurofibromin haploinsufficiency than others, affecting their development and function 
and leading to common manifestations seen in NF1.51 These cell types include, but are 
not limited to, the neural crest and neural crest derived cells, neural tube derived cells, 
and some mesoderm derived cells.51 
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 Neural crest cells seem particularly sensitive to changing neurofibromin levels.7 
Haploinsufficient neural crest cells (+/-) and their many derivatives lead to a plethora of 
the non-tumorous manifestations seen in NF1. These include abnormal pattern of 
colonization by melanocytes in the dermis during a key developmental window, leading 
to general hyperpigmentation, as well as abnormal melanocytic cells in the iris leading to 
Lisch nodules.51,52 Schwann cells and neurons of the PNS which are derived from neural 
crest cells are at higher risk of forming neurofibromas.51 Cardiac problems may arise if 
these neural crest cells do not properly form the endocardial cushion, a key step in heart 
development, and lead to congenital heart defects or contribute to other cardiovascular 
disease.51 Bone deformities may arise if the neural crest cells do not properly form the 
craniofacial bones, which can contribute to facial dysmorphisms seen in severe cases.49,51 
 In the CNS, haploinsufficiency can contribute to the loss of connections in the 
brain: specifically, patients with NF1 under MRI exhibit reduced anterior-posterior 
connectivity, and differences in local nerve connectivity, the latter correlating with IQ.53 
This can be attributed to haploinsufficient oligodendrocytes which, like the Schwann 
cells of the PNS, display abnormalities in the presence of low neurofibromin. 
Specifically, oligodendrocytes in patients with NF1 demonstrated split, decompacted 
myelin, which can alter the transmittance speed and efficiency of signals between 
neurons.54 Hypertrophic, non-tumorous astrocytic growth, caused by a lack of sufficient 
growth regulation in astrocytes by neurofibromin, can also contribute to the learning 
disorders seen in patients with NF1.29 
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 In the vasculature, some NF1 patients exhibit symptoms of chronic inflammation 
resulting in arterial aneurysm formation and possible mortality.36 Researchers have found 
that the reduced neurofibromin levels in a NF1 +/- myeloid cells is sufficient to recreate 
the conditions for aneurysm formation in vivo.36 This is attributed to the lack of 
regulation on pathways such as the Ras-GAP pathway, which make the myeloid cells 
more sensitive to growth factors and other stimuli, causing them to not only proliferate 
but become hyperactive and secrete their own growth factors and cytokines.36 These 
secreted cytokines can be responsible for arterial stenosis, hypertension, and aneurysm 
formation once myeloid cells begin to infiltrate the vessel walls.36 
  
“Second hit” tumor formation 
 Loss of the second, normal gene for neurofibromin in cells of patients with NF1 
can happen seemingly randomly over a patient’s lifetime, and leads to the other 
manifestations seen in NF1 such as tumor formation.7 This loss of heterozygosity, termed 
a “second hit” of mutation, parallels other types of cancer that usually only begin after 
multiple mutations in the genome.55 Many NF1 tumors can be traced to neural crest 
origin such as those involving Schwann and chromaffin cells. The origin of some other 
cancers can be traced to other developmental tissue, such as leukemia from mesodermal 
myeloid cells, or astrocytomas from ectodermal neural tube tissue.56 In patients with 
NF1, researchers have found that the loss of the second gene in Schwann cells leads to 
the tumorous neurofibromas, both cutaneous/dermal and plexiform variants, as well as 
the more aggressive MPNST.56 Although Schwann cells make up the bulk of a 
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neurofibroma, other cell types such as fibroblasts, mast cells and perineural cells, are 
found in greater amounts in the neurofibromas.57 Evidence suggests that a neurofibroma 
only forms when the other cell types around the Schwann cells are also haploinsufficient; 
healthy surrounding cells seem to prevent neurofibroma growth.56,57 Loss of 
heterozygosity in melanocytes leads to the café-au-lait spots that are so prominent in 
patients with NF1; heterozygosity in melanocytes can explain the subtle  general 
hyperpigmentation that patients have in comparison to their relatives or parents.56 In 
astrocytes, loss of heterozygosity leads to the formation of astrocytomas, whether they 
are benign and on the optic nerve or malignant and in other parts of the CNS.56 In the 
vasculature, myeloid cells. Chromaffin cells with “double hit” mutations can lead to 
pheochromocytomas and the endocrine and cardiovascular problems that follow suit.44 
  
Potential Future Therapies  
 The Ras-GAP pathway, which is hyperactive in these tumorous tissues, provides 
many downstream proteins that are ideal targets for current and future therapies. Anti-Ras 
drugs such as farnesyl transferase inhibitors have demonstrated some efficacy in fighting 
these tumors in clinical trials.44 Because the protein mTOR (mammalian target of 
rapamycin) is involved in the downstream effects of the Ras pathway, targeting this 
protein with rapamycin or similar drugs has also shown efficacy in fighting certain 
tumors, such as the plexiform neurofibroma.2,56  
More research is currently underway for therapies targeting the Ras pathway and 
other cellular growth pathways.2 Further research into predictive tests that can identify 
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patients at high-risk for specific abnormalities, and research into more variety of targeted 
biological therapies is needed.15 In all situations, the earlier that cancer is found and 
treatment begins, the better the chance for a positive prognosis for the patient.7  
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QUALITY OF LIFE 
 There are many ways to measure the quality of life (QoL) impact for patients 
suffering from a condition or disease. Some of the most popular ways include detailed 
surveys or questionnaires that patients or physicians fill out based on their own 
experiences. The aggregation is run through statistical tests to determine the average 
impact on various factors. For NF1, these surveys include the SF36 Health Survey 
Questionnaire (see appendix), which contains 36 questions covering 8 lifestyle and health 
categories.58 The patient chooses the best answer to each question, and each answer has a 
value between 0-100. The averages of the answer values to certain question numbers (e.g. 
#20 and 32 averaged together measures social functioning) can determine the impact of 
the disease on specific variables.58 Other surveys include the Skindex survey, which 
exists specifically to measure the QoL impact by skin diseases. Various answers to this 
29-item questionnaire are ranked and averaged, similar to the SF-36, to determine the 
impact on QoL for a range of aspects including emotions, physical symptoms, and 
functioning.59  
Patient population studies using the SF-36 and Skindex surveys demonstrate a 
negative impact by neurofibromatosis type 1 on all aspects of a patient’s life. Some 
studies suggest breaking down NF1’s impact on QoL into two categories: the disease’s 
severity and thus its effect on physiology, and its cosmetic impact and thus the disease’s 
effect on psychology.59 Patients overwhelmingly report a lower QoL in both categories, 
but the emotional impact due to NF1’s effect on the patient’s perceived social value and 
self-esteem was the greatest.59 Studies show that even if the majority of NF1 cases 
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fortunately contain mild internal manifestations and are non-severe in respect to 
pathophysiology, a patient’s own perception of the severity of his disease is directly 
related to the amount of cosmetic discordance which unfortunately is quite common in 
NF1.59 This can add unneeded fear to patients, in addition to the psychological impact 
already affecting patients in social settings due to the cosmetic detriment of the disease.59 
Physicians can use the knowledge from these studies in their future treatment of patients 
with NF1, by making fixing deformities a higher priority to help ease the mental health of 
the patients. 
A specific questionnaire exists for the impact to QoL on children with disabilities, 
termed the Behavior Assessment System for Children (BASC), which relies on the self-
reporting by children, teachers and parents to determine how they perceive a disability 
impacts the behavior of the child.60 
Patient population studies utilizing the BASC, specifically the second edition, 
found that children with NF1 are greatly impacted socially and emotionally, particularly 
in school. Some studies suggest that these impacts may be due to underlying leaning 
disorders common in people with NF1 which can also affect their social skills; however, 
cosmetic appearances may also contribute to social exclusion and teasing by peers.61 In 
particular, children with NF1 tested low in “Leadership and Functional Communication” 
implying unpopularity and fewer reciprocated friendships.61 Social problems such as 
bullying, and behavioral problems such as depression, anxiety or aggression, were 
common in children with NF1. Researchers attribute the lack of social skills to 
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underlying neurocognitive defects and the stresses of school.61 Thus, therapy targeting a 
patient’s learning disorders can be effective in improving a child’s social status in school. 
The level of impact on the quality of life for patients with neurofibromatosis type 
1 varies greatly based on the level of expression of the mutation in the affected 
individual. There are many aspects of the patients’ and the patients’ families’ lives that 
can be affected when dealing with the management and treatment of neurofibromatosis 
type 1 (Table 6). These aspects can range from physical and emotional burden to 
financial burden, as health or life insurance providers may charge high deductibles or 
choose not to cover the patient at all due to expected high medical costs.7 
Table 6. Quality of life aspects impacted by NF1. 
Aspects that can impact quality of life include: 
Academic challenges and learning disorders 
Discrimination for employment 
Discrimination for health insurance/life insurance coverage 
Disfigurement 
Fear of malignancy 
Lack of physical activity (if bone deformities are present) 
Out-of-pocket expenses by patient or family 
Orthopedic problems and having to wear corrective brace 
Pain 
Pregnancy complications and the risk of passing NF1 onto child 
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Psychosocial issues due to lack of self-esteem and confidence 
Social exclusion and stigmatization 
Time consuming, repetitive clinical visits for check-ups or removing neurofibromas 
Vision loss 
Compiled from: Korf BR, Rubenstein AE. Neurofibromatosis: a Handbook for Patients, 
Families, and Health Care Professionals. New York: Thieme Medical Publishers; 2005 
 
The following are cases of people with neurofibromatosis type 1 demonstrating 
how the disease has impacted their life. As the following individual cases are discussed, 
the impacting factors on the patient’s life will be discussed more fully. 
 
Sandra O. and pregnancy  
Sandra was diagnosed with neurofibromatosis type 1 shortly after birth. The 
diagnosis was made primarily due to the many café-au-lait spots present on her skin. As 
she grew older, cutaneous neurofibromas began to form as well. Up until adulthood, her 
manifestations were relatively mild. The greatest impact on the quality of life in her 
childhood and teenage years were psychosocial. She would feel the need to often wear 
long sleeve clothing to cover her skin, would be afraid to participate in activities such as 
swimming or beach days with friends, felt depressed at times, and would often take trips 
to the dermatologist to remove any cutaneous neurofibromas (sometimes flying to 
different cities to do so).  A deep tumor formed in her foot during teenage years, causing 
pain when walked upon, and requiring excision with surgery. Fortunately, she suffered no 
apparent learning disorders. With her endearing personality and the positive support of 
her family and friends, she overcame any academic or social challenge posed to her by 
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NF1 to live a successful adult life. As an adult she wished to have children but was 
warned against doing so by physicians who worried that hormonal imbalances from 
pregnancy may aggravate her condition. After trying and failing to have a child, her 
condition did indeed worsen. Malignant glioblastoma tumors began forming in her brain, 
specifically grade III or IV astrocytomas, and which have a poor prognosis. Sandra kept a 
positive outlook on life, an important aspect to fighting cancer, but after much surgery, 
radiation, and chemotherapy, the cancer persisted and she ultimately succumbed to her 
disease at 39 years of age. 
 The information on the relationship between pregnancy and neurofibroma is still 
quite limited. Because NF1 is an autosomal dominant mutation, there is a 50% chance 
that an offspring will have the mutation as well.62 Genetic counseling exists to help 
potential parents with NF1 to understand their disease and the risk factors involved. This 
knowledge factors into the decision-making by patients on whether or not to have 
children, with some patients opting out of childbirth altogether.63 In one study 44% of 
subjects stated that the knowledge of the risk of NF1 factored into their pregnancy 
decision, with another 34% expressing that it would have influenced their decision had 
they known about the risk beforehand.63 
Parental age may also play a role in the chance of sporadic mutations in NF1 
patients with no familial history.64 One study reviewing two decades of the general Czech 
population found that, as the mean parental age of the Czech population has increased, so 
too has the incidence of NF1.64 They concluded that advanced parental age can affect 
sporadic mutations, with more bearing on paternal rather than maternal age. They found 
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that the mean paternal age of sporadic NF1 patients was 3.7 years older than the general 
population, versus 1.7 years older than the general population for mothers.64 
In respect to hormone imbalances due to pregnancy, some studies suggest that the 
increase in hormone levels from pregnancy can aggravate symptomatic manifestations 
and lead to an increase in the number and size of cutaneous or subcutaneous 
neurofibromas developing on the skin and elsewhere.65 Pelvic or uterine neurofibroma 
development, or pelvic bone deformity, can cause pain during pregnancy, block the 
descent of the child, and require a caesarian section. In one population study for NF1 
women bearing children, the rate of caesarian section, at 36.1%, was much higher than 
the general population average of 9-20%.65 Over 80% of women subjects also reported 
new or further growth of existing neurofibromas during pregnancy.65 This may be due to 
an increased expression of progesterone receptors, found on 75% of neurofibroma cells, 
and to a lesser extent estrogen receptors, found on 5% of neurofibroma cells.66 In 
contrast, no normal nerve samples showed progesterone receptor expression.67 
Interestingly, the plexiform variant of neurofibromas may be less susceptible to growth 
based on raised hormone levels than the cutaneous and dermal variants; however, 
malignant peripheral nerve sheathe tumors (MPNST) were still susceptible to increased 
growth from these hormones.67 Progesterone receptors are also found expressed in 
astrocytomas in the brain, while normal astrocytes do not express such receptors, 
suggesting an influence of raised progesterone levels on increased brain tumor frequency 
as well.67 Due to these steroids’ role as stimulatory agents of neurofibroma growth, future 
therapeutics may target the level of these steroids to treat neurofibromas.66 
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Susan G. and pain, surgery and familial stress 
Susan was born with NF1 manifestations such as café-au-lait spots that doctors 
initially just believed were birthmarks.7 However as a newborn she cried incessantly, 
demonstrating signs of pain. At 16 months, Susan had blood in her urine, leaving the 
toilet bowl red.7 Doctors discovered a mass blocking the ureter, a neurofibroma, and 
diagnosed Susan with NF1. The tumors that began early for Susan would become the 
cause of significant pain for her, and the beginning of many stresses the family would 
have to bear. As Susan’s mother, Dolores, described it “it’s not that one person in the 
family has NF; it’s that the whole family has NF.” These familial stresses included 
feelings of guilt, and blame shifting by Dolores and her husband, and their respective 
parents, on whose genetics may have contributed to the disease.7 Dolores also felt 
Susan’s sisters, who were not diagnosed with NF1, may have felt neglected in respect to 
how much attention Susan received. Over Susan’s lifetime, she required over 40 surgeries 
both major and minor, and the time and expenses for these contributed to the familial 
stress.7 Dolores would schedule surgeries on holidays so Susan could miss the least 
amount of school. Susan also suffered from learning disorders, including poor 
handwriting and poor math skills, and required private tutoring and enrollment in private 
school, both of which added to the financial burden of the family.7 
Susan suffered from neurofibromas all over her body, including the feet, arms, 
scalp, above the eye, and eyebrows. The cranial neurofibromas caused a lot of headaches, 
and required invasive surgery that caused scars and more pain during recooperation. 
Plexiform neurofibromas developed internally and led to further internal pain; for 
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instance, a persistent tumor on the bladder made urination difficult and required extensive 
bladder surgery.7 Susan required multiple prescription medications to manage the pain. 
She was very resilient in overcoming the physical and academic challenges that came her 
way, insisting on going to college despite her guidance counselor’s advice against it.  She 
married and lived a happy life until her NF1 complications overwhelmed her. She 
ultimately passed away at 34.7 
Pain, other than from headaches and migraines, is relatively uncommon in NF1 
but can manifest itself in various ways.12 Headaches and migraines, which affect about 
20% of NF1 patients, can be treated with the usual prophylactic medication.12 Cutaneous 
neurofibromas can be painful when they are erupting, or when traumatized once full 
grown. Paraspinal plexiform neurofibromas can cause spinal root and back pain.12 
Orthopedic problems such as scoliosis or pseudarthrosis, along with the corrective 
surgery or brace, can also lead to pain.68 Neurofibromas that grow in the fingers or feet 
and pinch nerves or are constantly exposed to trauma can lead to extreme pain and need 
to be removed surgically.68 Finally, sudden pain can be due to the formation of a 
malignant peripheral nerve sheathe tumor, which is highly aggressive and associated with 
invariable severe pain. MPNST needs to be diagnosed early before it quickly 
metastasizes, as it does not respond well to chemotherapy or radiation and must be 
excised surgically.12 Due to the lethality and spontaneity of MPNST, NF1 patients 
complaining about pain should be examined carefully by their physician for signs of 
MPNST through ultrasound or X-Ray.15 
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Ana R. and social exclusion 
 Ana was born in Mexico with a red mark on her face she describes as looking 
“like a bee sting”: an early neurofibroma.69 As she grew older, it too grew in size, and 
began to slowly encompass an entire side of her face. Her parents moved to the U.S. to 
find Ana better health care for her condition and she was diagnosed with NF1 and treated 
for her tumors at Loma Linda University Medical Center. However, her facial tumor 
rapidly grew back, and more developed all over her body with age.69 
 Ana suffered from depression as a child, stating that kids her age would ask her 
why she looked the way she did, how she just wished she looked like her friends, and 
wished to know as a child “why God was so mean? I felt like I did something wrong.”69 
She became reluctant to go to school out of fear for how she would be treated. She 
remembers how some other kids would cry when they saw her. Other times, she would be 
stopped on the street and blessed by strangers; although she felt mentally and physically 
normal, her treatment by others made her made her feel shy and isolated.70 Ana 
ultimately selected not to finish her college coursework, feeling discriminated against by 
administration who offered her disabled services. She also tried to get a job but felt 
discriminated by employers based on her appearance. She was likened to the elephant 
man, Joseph Merrick, by people who saw her. Ultimately, Ana secluded herself from 
public as much as possible and left the house about once a month.69 At age 22 when the 
tumor was so big it started impacting her vision and causing headaches, she visited a 
team of doctors who began a series of 5 reconstructive surgeries to remove the tumor and 
improve Ana’s appearance.69,70 The cosmetic improvement that occurred to Ana 
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following surgery changed her life. She felt as if the world opened up to her. She 
developed confidence and now leaves the house often, no longer feeling threatened by 
strangers. She has made new friends and began dating, returned to school, and is working 
towards becoming a cosmetologist.70 She is unwilling to have children, however, out of 
fear of passing on her disease. She now wishes to help others who may be sheltering 
themselves from society.69 
 Stories of psychosocial issues and societal exclusion are common among patients 
with visible manifestations of NF1. Psychological issues develop even in patients with 
mild manifestations, and some studies show that a greater severity of skin manifestations 
does not correlate to a greater level of emotional problems impacting the patient.71 The 
number of symptoms for anxiety and depression are higher in patients with NF1 than the 
general population, and even higher than in patients with other chronic diseases, such as 
various forms of cancer.71 Patients may not feel comfortable wearing certain clothing, 
and may feel traumatized in social settings whether making new friends at school, 
interviewing for jobs, or trying to date. Unfortunately, the stigma for NF1 being “the 
elephant man’s disease” still persists today, even among some physicians who may be 
uneducated on the difference between Proteus Syndrome and NF1.72 The on-going 
stigmatization only makes it harder for patients and their families to feel and be treated as 
normal. Patients and family members aware of Joseph Merrick’s story, but unaware of 
the difference between NF1 and Proteus Syndrome, can become worried that mild NF1 
manifestations will degenerate into something more disfiguring.72 
 41 
Suggestions to improve quality of life for NF1 Patients 
 The best way to improve the quality of life for patients with mild and non-life 
threatening manifestations is by educating the public on NF1 and destigmatizing the 
condition.71,72 There are still limits to the amount of cosmetic improvement that can be 
bestowed onto patients, and removing the negative stigma from society through education 
will go a long way in helping these patients feel comfortable acquiring jobs and 
socializing, without the fear of alienation or scaring others way.72 Teachers who are 
educated about NF1 will understand that a student with the condition may have learning 
disabilities and not a lack of intelligence, and employers who are educated would 
understand that the condition is not contagious and will not spread to customers.72 Patient 
and family education about the condition can also help; the participation in support 
groups that focus on alleviating any psychological issues or stress related to the disease 
can help patients feel more comfortable within their own body, and more understanding 
of the severity (or lack-there-of) of their condition to help alleviate fear.71,72 
 Beyond public education, physicians should treat, to the best of their ability, the 
various patient-specific manifestations that occur with NF1. The goal of management 
should be to improve not only the patient’s physiological health, but also the patient’s 
psychological health, which can do wonders to alleviate the many of the stresses that 
patients carry.71,72,73 For manifestations that affect quality of life through physiological 
debility such as scoliosis, vision loss or pain from neurofibromas, corrective bracing or 
appropriate surgical procedures should be used to alleviate the debilitating symptoms and 
allow the patient to function normally.12 Cosmetic manifestations should not be ignored, 
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and neurofibromas should be should be surgically removed when possible to prevent 
visible outgrowths from causing psychological or social damage, as well as treating the 
café-au-lait spots with hydroquinone or laser therapy to correct the hyperpigmentation.74 
Research shows that improving the patient’s cosmetic look helps them lead more 
fulfilling lives with respect to their social and occupational settings.73 
 Learning disabilities such as depression should be treated with the appropriate 
therapy and programs to prevent patients from feeling inferior amongst their peers and 
leave them capable of academic and occupational success.7,75 If possible, families should 
opt for tutoring and/or enroll the patient in programs designed to overcome the specific 
learning disorder.7 Psychosocial issues such as depression may be secondary to other 
problems, such as feelings of inferiority due to a learning disability or cosmetic feature, 
and may be remedied by fixing the primary cause.71 Therefore, along with therapy, 
researchers should develop medications that can ameliorate the primary causes of a 
learning disabilities. For example, lovastatin has shown efficacy in treating specific 
learning disabilities, such as spatial and behavioral learning deficits, in mice.56 However, 
studies in children with similar statin, simvastatin, have yet to demonstrate the same 
cognitive improvements in human trials.56 
 Finally, the quality of life for patients can be improved by scheduling routine 
check-ups with knowledgeable physicians who can detect early signs of symptoms such 
as learning disorders or malignancies.7,12  It is particularly important to detect any 
learning disorders early on in children, such as ADD or speech problems, as that can 
greatly help a child’s academic and social life.12 Check-ups are also important for 
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catching MPNSTs early, which can develop from plexiform neurofibromas and 
metastasize rapidly, as well as cause severe pain.15 Annual eye exams are important for 
monitoring vision and preventing vision loss, headaches, or endocrine imbalances, should 
a tumor begin developing along the optic nerve.7,12 Catching other types of tumors early, 
such as pheochromocytomas should a patient present with excessive sweating and 
irregular blood pressure, or grade III or IV astrocytomas should a patient present with 
abnormal headaches, would provide a great advantage in cancer therapy and may prevent 
these tumors from becoming lethal.12  
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METHOD OF EVIDENCE ACQUISITION 
 I performed PubMed and Google Scholar searches of the English-language 
literature (from 1968 to 2016) using the terms neurofibromatosis, neurofibromatosis 
management, neurofibromatosis quality of life, neurofibromatosis pathogenesis, 
neurofibromatosis history, neurofibromatosis review, neurofibromatosis and pregnancy, 
clinical neurofibromatosis, elephant man, neurofibromatosis family and more. I searched 
textbooks and articles online about people living with neurofibromatosis to represent 
cases for quality of life. Relevant bibliographies of literature were manually reviewed for 
additional resources. 
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